95 related articles for article (PubMed ID: 32146796)
1. Hepatocellular carcinoma - clinicopathological characteristics, survival, and expression of various histologic molecular markers.
Nikolova D; Ivanova V; Dimitrova M; Jovanovik R; Kunovska S; Orovcanec N; Petrushevska G; Janevska V
Pol J Pathol; 2019; 70(4):269-276. PubMed ID: 32146796
[TBL] [Abstract][Full Text] [Related]
2. Expression of P-aPKC-iota, E-cadherin, and beta-catenin related to invasion and metastasis in hepatocellular carcinoma.
Du GS; Wang JM; Lu JX; Li Q; Ma CQ; Du JT; Zou SQ
Ann Surg Oncol; 2009 Jun; 16(6):1578-86. PubMed ID: 19290490
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.
Felipe-Silva A; Wakamatsu A; Dos Santos Cirqueira C; Alves VA
World J Gastroenterol; 2016 Jul; 22(27):6246-56. PubMed ID: 27468214
[TBL] [Abstract][Full Text] [Related]
4. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
Prange W; Breuhahn K; Fischer F; Zilkens C; Pietsch T; Petmecky K; Eilers R; Dienes HP; Schirmacher P
J Pathol; 2003 Oct; 201(2):250-9. PubMed ID: 14517842
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma.
Lin YC; Wu MY; Li DR; Wu XY; Zheng RM
World J Gastroenterol; 2004 Nov; 10(22):3235-9. PubMed ID: 15484291
[TBL] [Abstract][Full Text] [Related]
6. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma.
Peng SY; Chou SP; Hsu HC
J Hepatol; 1998 Aug; 29(2):281-9. PubMed ID: 9722210
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
8. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of E-cadherin expression in hepatocellular carcinoma: correlations with clinical features.
Dobrescu AE; Basa SN; Cornianu M; Lazăr DC; Suciu SC; Tudor A; Viţa OC; Tarţă-Marcu DC; Barna RA; Lazăr OF
Rom J Morphol Embryol; 2019; 60(4):1243-1251. PubMed ID: 32239101
[TBL] [Abstract][Full Text] [Related]
11. Nuclear EpICD expression and its role in hepatocellular carcinoma.
Park SY; Bae JS; Cha EJ; Chu HH; Sohn JS; Moon WS
Oncol Rep; 2016 Jul; 36(1):197-204. PubMed ID: 27176150
[TBL] [Abstract][Full Text] [Related]
12. Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma.
Adachi M; Kai K; Yamaji K; Ide T; Noshiro H; Kawaguchi A; Aishima S
Histopathology; 2019 Jul; 75(1):63-73. PubMed ID: 30811632
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
14. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer.
Lim SC; Lee MS
Oncol Rep; 2002; 9(5):915-28. PubMed ID: 12168049
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of SLC5A8 inhibits hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling.
Hu BS; Xiong SM; Li G; Li JP
Tumour Biol; 2016 Oct; 37(10):13445-13453. PubMed ID: 27465549
[TBL] [Abstract][Full Text] [Related]
16. Expression of the G1-S modulators in hepatitis B virus-related hepatocellular carcinoma and dysplastic nodule: association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma.
Choi YL; Park SH; Jang JJ; Park CK
J Korean Med Sci; 2001 Aug; 16(4):424-32. PubMed ID: 11511787
[TBL] [Abstract][Full Text] [Related]
17. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes.
Cui J; Zhou X; Liu Y; Tang Z; Romeih M
J Gastroenterol Hepatol; 2003 Mar; 18(3):280-7. PubMed ID: 12603528
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness.
Tsujikawa H; Masugi Y; Yamazaki K; Itano O; Kitagawa Y; Sakamoto M
Hum Pathol; 2016 Apr; 50():24-33. PubMed ID: 26997435
[TBL] [Abstract][Full Text] [Related]
19. Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma.
Liu XH; Pan MH; Lu ZF; Wu B; Rao Q; Zhou ZY; Zhou XJ
Dig Liver Dis; 2008 Jul; 40(7):560-7. PubMed ID: 18294932
[TBL] [Abstract][Full Text] [Related]
20. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice.
Anna CH; Iida M; Sills RC; Devereux TR
Toxicol Appl Pharmacol; 2003 Jul; 190(2):135-45. PubMed ID: 12878043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
